Rosetta Genomics Appoints Kevin Watson
News Feb 20, 2014
Rosetta Genomics Ltd. has announced the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care.
Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.
"We are delighted to welcome Kevin to the Rosetta team to drive our reimbursement and managed care strategy and initiatives. Reimbursement is critical for commercial success and, as 2014 is a year of commercial execution for Rosetta, this is a timely and important hire for us," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Kevin's experience devising strategic marketing, growth, and operational plans directed to the payer, integrated health system, hospital and distributor channels will be an invaluable asset for Rosetta as we execute our commercial plans for our current suite of cancer testing services and plan for the launch of future microRNA-based diagnostics."
Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement. Prior to this, Mr. Watson was the President of GlobalPayer, a payer relations and reimbursement consulting and outsourcing company serving providers and manufacturers in the medical device and diagnostic industry.
Mr. Watson was the Regional Marketing/Payer Relations Director at Becton Dickinson Diagnostics - TriPath Imaging for 6 years, where he was responsible for the development, execution and management of reimbursement outcomes with large payer organizations, Medicare and Medicaid.
Previous to that, Mr. Watson held positions as Executive Director, Business Development at LabCorp., and Network Product Development Leader, Executive Director with Quest Diagnostics, Inc. Mr. Watson started his career in payer management at Aetna Health Plans, where he spent four years as Administrator, National Vendor Contracting.
"This is an exciting time to be joining Rosetta to develop and manage the Company's payer relations strategy," said Kevin Watson. "Rosetta's cancer testing services provide critical and objective diagnostic data that may help physicians to select optimal treatment options and improve patient outcomes. I am looking forward to working with the Rosetta team as we build and expand the Company's microRNA diagnostic product offerings to bring truly personalized medicine to patients."
A Rogue Gene is Causing Seizures in Babies. Here’s How MSU Wants to Stop itNews
The researchers are closer to understanding the source of the seizures, a gene known as GNAO1 and the transformations it can take on, and potentially stopping its devastating effects by uncovering key differences in the way it functions.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018